ANVS
Annovis Bio, Inc.
NYSE · USHealthcareBiotechnology
$1.69-2.87%
Price as of Jul 20, 2026
ANVS growth
Annovis Bio, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- —
- EBITDA
- -67.6%
- EBIT
- -64.6%
- EPS
- +20.4%
- Free cash flow
- -15.6%
- Operating cash flow
- -15.6%
Forward estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +16.8%
Three-year CAGR
- Revenue
- —
- EBITDA
- -26.9%
- EBIT
- -11.2%
- Net income
- -17.3%
- EPS
- +99.9%
- Free cash flow
- -17.0%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.